NCT06833073 2026-04-06
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
Clinical Trials
11 trialsNCT01697306 2025-01-30
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
A.O.U. Città della Salute e della Scienza
Phase 2 Completed
NCT06187506 2024-07-12
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Fudan University
Phase 2 Recruiting
NCT00694915 2021-08-17
STCC
Cadila Pharnmaceuticals
Phase 2 Completed
NCT01373294 2019-08-06
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00003715 2015-12-03
Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
AVAX Technologies
Phase 2 Terminated
NCT00003386 2013-04-11
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
GOG Foundation
Phase 2 Terminated
NCT00004122 2013-02-01
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00003759 2013-01-31
AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00023842 2012-09-24
BCG With or Without Mitomycin in Treating Patients With Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00514072 2012-08-09
Vaccine Therapy in Treating Patients With Stage D0 Prostate Cancer
Kael-GemVax Co., Ltd.
Phase 2 Unknown